A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

被引：0
|
作者：
Maureen Watt
Charles McCrea
Sukhvinder Johal
John Posnett
Jameel Nazir
机构：
[1] Astellas EMEA,
[2] PAREXEL Access Consulting,undefined
[3] Astellas Pharma Europe Ltd.,undefined
来源：
Infection | 2016年 / 44卷
关键词：
Cost-effectiveness; Budget impact; Fidaxomicin; Vancomycin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：599 / 606
页数：7
相关论文
共 50 条
  • [1] A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany
    Watt, Maureen
    McCrea, Charles
    Johal, Sukhvinder
    Posnett, John
    Nazir, Jameel
    INFECTION, 2016, 44 (05) : 599 - 606
  • [2] Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan
    Okumura, Hiroyuki
    Ueyama, Maki
    Shoji, Shingo
    English, Marci
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2020, 26 (06) : 611 - 618
  • [3] Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France
    Watt, Maureen
    Dinh, Aur Elien
    Le Monnier, Alban
    Tilleul, Patrick
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (07) : 678 - 686
  • [4] A retrospective budget impact analysis of fidaxomicin treatment for Clostridioides difficile infections (CDI) in Germany
    Siefen, Ann-Cathrine
    Kurte, Melina Sophie
    Bauer, Anna Marie
    Cornely, Oliver A.
    Wingen-Heimann, Sebastian
    Kron, Florian
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 933 - 942
  • [5] Cost-Effectiveness of Fidaxomicin for Clostridium difficile Treatment
    Simon, Matthew S.
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (04)
  • [6] Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States
    Stranges, Paul M.
    Hutton, David W.
    Collins, Curtis D.
    VALUE IN HEALTH, 2013, 16 (02) : 297 - 304
  • [7] Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain
    Carlos Rubio-Terrés
    José María Aguado
    Benito Almirante
    Javier Cobo
    Santiago Grau
    Miguel Salavert
    Elena González Antona Sánchez
    Cristina López Gutiérrez
    Darío Rubio-Rodríguez
    European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 : 1105 - 1111
  • [8] Extended-pulsed fidaxomicin versus vancomycin in patients 60years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain
    Rubio-Terres, Carlos
    Maria Aguado, Jose
    Almirante, Benito
    Cobo, Javier
    Grau, Santiago
    Salavert, Miguel
    Antona Sanchez, Elena Gonzalez
    Lopez Gutierrez, Cristina
    Rubio-Rodriguez, Dario
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2019, 38 (06) : 1105 - 1111
  • [9] Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection
    Chen, Jiahe
    Gong, Cynthia L.
    Hitchcock, Matthew M.
    Holubar, Marisa
    Deresinski, Stanley
    Hay, Joel W.
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (10) : 1448 - 1454
  • [10] Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
    Jiang, Yiling
    Sarpong, Eric M.
    Sears, Pamela
    Obi, Engels N.
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (01) : 111 - 126
12345